Gray matter damage predicts the accumulation of disability 13 years later in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 8, 2013
- Accepted in final form July 11, 2013
- First Published October 11, 2013.
Article Versions
- Previous version (October 11, 2013 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Massimo Filippi, MD,
- Paolo Preziosa, MD,
- Massimiliano Copetti, PhD,
- Gianna Riccitelli, PhD,
- Mark A. Horsfield, PhD,
- Vittorio Martinelli, MD,
- Giancarlo Comi, MD and
- Maria A. Rocca, MD
- Massimo Filippi, MD,
TEVA, Genmab
NONE
Bayer-Schering, Biogen-Idec, Genmab, Merck-Serono, Teva
Editor in CHief, Journal of Neurology. Editorial Board Member: AJNR, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Alzheimer's Disease, Journal of Neuroimaging, Journal of Neurovirology, Lancet Neurology, Magnetic Resonance Imaging, Multiple Sclerosis, Neurological Sciences
NONE
NONE
NONE
Consultancies: Bayer-Schering, Biogen-Idec, Genmab, Merck-Serono, Novartis, Teva
Bayer-Schering, Biogen-Idec, Genmab, Merck-Serono, Teva.
NONE
NONE
Grant/research support from: 1) Commercial entity: Bayer-Schering2) Commercial entity: Biogen-Idec3) Commercial entity: Genmab4) Commercial entity: Merck-Serono5) Commercial entity: Novartis6) Commercial entity: Teva
1) Italian Ministry of Health; grant number: RF-2010-2313220; role: P.I.; duration: December 2012-November 2015
NONE
1) Fondazione Italiana Sclerosi Multipla (FISM)2) CurePSP
NONE
NONE
NONE
NONE
NONE
NONE
- Paolo Preziosa, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Massimiliano Copetti, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gianna Riccitelli, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mark A. Horsfield, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Xinapse Systems Ltd
NONE
NONE
NONE
NONE
NONE
- Vittorio Martinelli, MD,
NONE
NONE
Dr Martinelli has received travel supports and speaker fees for activities with Biogen Domp?, Merck/Serono, Bayer Schering, Teva and Sanofi Aventis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giancarlo Comi, MD and
In the last two years, I have received personal compensation as a member of Scientific Advisory Boards from commercial entities: 1)Bayer Schering, 2) Merck Serono International, 3) TEVA Pharmaceutical Ind. Ltd., 4) Sanofi-Aventis, 5) Genzyme, 6) Novartis 7) Actelion
NONE
In the past two years I have received honoraria for speaking activities from 1) TEVA Pharmaceutical Ind. Ltd, 2) Sanofi-Aventis, 3) Genzyme, 4) Serono SymposiaInternational Foundation, 5) Biogen, 6) Merck Serono,7)Novartis, 8)Bayer Schering
1) Neurological Sciences, associate editor, 2011-2013
NONE
NONE
NONE
In the last two years, I have received personal compensation as a member of Scientific Advisory Boards from commercial entities: 1)Bayer Schering, 2) Merck Serono International, 3) TEVA Pharmaceutical Ind. Ltd., 4) Sanofi-Aventis, 5) Genzyme, 6) Novartis 7) Actelion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria A. Rocca, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Serves as consultant to Biogen idec and serono symposia
Received speaker honoraria from Biogen Idec and Serono Symposia International Foundation
NONE
NONE
NONE
Italian Ministry of Health GR-2008-1138784, PI, from 2011 to 2013 GR-2009-1529671, PI, from 2012 to 2014 Fondazione Italiana Sclerosi Multipla, FISM 2012/R/15 2012-2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuroimaging Research Unit (M.F., P.P., G.R., M.A.R.), Institute of Experimental Neurology, and Department of Neurology (M.F., P.P., V.M., G.C., M.A.R.), San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan; Biostatistics Unit (M.C.), IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy; and Medical Physics Group (M.A.H.), Department of Cardiovascular Sciences, University of Leicester, Leicester Royal Infirmary, UK.
- Correspondence to Prof. Filippi: filippi.massimo{at}hsr.it
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
A magnetization transfer histogram study of normal-appearing brain tissue in MSC. Tortorella, B. Viti, M. Bozzali et al.Neurology, January 11, 2000 -
Articles
Comparison of MS clinical phenotypes using conventional and magnetization transfer MRIM. Filippi, G. Iannucci, C. Tortorella et al.Neurology, February 01, 1999 -
Views and Reviews
MRI features of benign multiple sclerosisToward a new definition of this disease phenotypeM. Rovaris, F. Barkhof, M. Calabrese et al.Neurology, May 11, 2009 -
Articles
Increased tissue damage and lesion volumes in African Americans with multiple sclerosisB. Weinstock-Guttman, M. Ramanathan, K. Hashmi et al.Neurology, January 20, 2010